BioCentury
ARTICLE | Product Development

Sputnik V on par with other COVID-19 vaccines before and after boost

February 3, 2021 2:55 AM UTC

Phase III data in The Lancet revealed Russian COVID-19 vaccine Sputnik V has efficacy on par with other leading vaccines across several groups: the full population, those who had not yet received a second dose, and the elderly.

The vaccine’s efficacy of 91.6% in the full population was reported in December by N.F. Gamaleya Scientific Research Institute of Epidemiology and Microbiology and the Russian Direct Investment Fund. New data from the study showed it had 73.6% efficacy before administration of the second shot. The pre-boost data are based on 31 symptomatic COVID-19 cases that occurred between days 15 and 21 after the first dose, and is in line with the 72% efficacy in U.S. volunteers in J&J’s single-shot Phase III trial of JNJ-78436735, also an adenovirus vector vaccine...